文献速递肾癌与肾肿瘤

改善肾细胞癌患者的共享决策:SDM-RCC研究结果

Improved Shared Decision-making for Patients with Renal Cell Carcinoma: Results of the SDM-RCC Study.
PubMed 文献 · Eur Urol Oncol · 2026-06-04

这项多中心前瞻性前后对照研究纳入局部或转移性透明细胞肾细胞癌成人患者,实施包含患者决策辅助工具和医护人员培训的共享决策干预。干预后OPTION-5评分显著提高(47.2至60.5,均差13.2,95%CI 8.7-17.8,p<0.001),医护人员报告的SDM和ACEPP子量表1A也改善,但患者报告的SDM和决策偏好未变。

要点

  • SDM干预后观察者评定的患者参与决策(OPTION-5)显著提高。
  • 医护人员报告的SDM改善,但患者感知的参与度未变。
  • 决策冲突量表不确定性评分显示更多冲突,决策偏好未变。

核心结论

  • 实施SDM干预与观察者和医护人员报告的SDM显著改善相关,但患者感知的参与度保持相似。
  • 建议将SDM干预整合到常规肾细胞癌诊疗中以促进以患者为中心的决策。

研究设计与样本

  • 多中心前瞻性前后对照研究,纳入局部肾细胞癌或转移性透明细胞肾细胞癌成人患者。
  • 前测组接受标准诊疗,后测组在SDM干预实施后纳入。

主要发现

  • 干预后OPTION-5评分从47.2增至60.5,均差13.2(95%CI 8.7-17.8),p<0.001。
  • 大多数医院和所有OPTION-5条目均有改善。
  • 医护人员报告的SDM和ACEPP子量表1A均提高(两者p<0.001)。
  • 患者报告的SDM保持不变。
  • 咨询次数和时长增加,DCS不确定性评分显示更多冲突,CPS保持不变。

关键数值与推荐

  • 主要结局为OPTION-5评分,测量患者参与决策程度。
  • 次要结局包括医护人员和患者报告的SDM及决策质量(如DCS、CPS)。
  • 探索性结局包括生活质量、决策过程质量(ACEPP子量表1A)和过程指标(如治疗决策)。
  • 使用混合效应回归模型,以医院为随机截距。

临床怎么用

  • 可将患者决策辅助工具和医护人员培训组成的SDM干预纳入肾细胞癌常规诊疗。
  • 需关注患者感知参与度未改善及决策冲突不确定性增加的情况。

局限性

  • 前后对照设计限制了因果推断。
  • 患者报告的SDM未改善,DCS不确定性评分显示更多冲突。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: To improve shared decision-making (SDM) for renal cell carcinoma (RCC), we implemented an SDM intervention consisting of a patient decision aid and health care professional (HCP) training. This study evaluates its effectiveness. DESIGN, SETTING, AND PARCTICIPANTS: Multicenter prospective pretest-post-test study including adults with localized RCC or metastatic clear cell RCC. The pretest group received standard care; the post-test group was included after SDM intervention implementation. OUTCOME MEASUREMENT AND STATISTICAL ANALYSIS: The primary outcome was the Observing Patient Involvement in Decision-making (OPTION)-5 score, measuring patient involvement. Secondary outcomes included HCP- and patient-reported SDM and decision quality (eg, Decisional Conflict Scale [DCS], Control Preference Scale [CPS]). Exploratory outcomes were quality of life, quality of the decision-making process (ie, Assessing Communication about Evidence and Patient Preferences [ACEPP] subscale 1A), and process indicators (eg, treatment decision). Mixed-effects regression model with random intercepts for hospital was used. RESULTS AND LIMITATIONS: Post-test, OPTION-5 scores increased significantly (47.2-60.5; mean difference 13.2; 95% CI [8.7-17.8]; p < 0.001), with improvements across most hospitals and all OPTION-5 items. HCP-reported SDM and ACEPP subscale 1A also increased (both p < 0.001), while patient-reported SDM remained unchanged. The number and duration of consultations increased, and DCS uncertainty scores showed more conflict, while the CPS remained unchanged. The pretest-post-test design minimized inter-hospital workflow variation and supported sustained behavioral change but limits causal inference. CONCLUSIONS: Implementation of an SDM intervention was significantly associated with observed and HCP-reported SDM, while patient-perceived involvement remained similar. These findings suggest integrating the SDM intervention into routine RCC care to promote patient-centered decision-making.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bresser CC, Garvelink MM, van Dijk T, et al. Improved Shared Decision-making for Patients with Renal Cell Carcinoma: Results of the SDM-RCC Study. Eur Urol Oncol. 2026. PMID: 42242942. doi:10.1016/j.euo.2026.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。